Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/r HR MDS) Topline read-out from the Phase II BEXMAB trial confirms earlier positive findings ...

急性髓系白血病（AML）常见于老年患者，高强度化疗预后不佳。研究人员开展了低强度治疗的系统性回顾和网络荟萃分析。结果显示，AZA + VEN、LDAC + glasdegib 等方案疗效突出。该研究为老年 AML 患者治疗提供依据，意义重大。

TURKU, FI / ACCESS Newswire / April 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/ ...

Historically, BPDCN treatment relied on chemotherapy regimens adapted from leukemia or lymphoma protocols. However, recent breakthroughs have transformed the treatment paradigm. ELZONRIS (Stemline ...